drugset
drugset / Trial / NCT05990725

Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis

NCT05990725 ↗

Phase 3 Completed 260 enrolled Almirall, S.A.
NaSingle-groupOpen-labelTreatment

Summary

The main purpose of this study is to evaluate the effectiveness of 24 weeks of lebrikizumab in improving disease severity, signs, and symptoms in adults and adolescents with moderate-to-severe atopic dermatitis (AD).

Timeline

Start
2023-11-20
Primary completion
2025-06-25
Completion
2025-06-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Lebrikizumab Monoclonal antibody 250 mg Subcutaneous

Indications

atopic eczema